Compare NCPL & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NCPL | RDHL |
|---|---|---|
| Founded | 1984 | 2009 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.2M | 3.3M |
| IPO Year | 2022 | 2012 |
| Metric | NCPL | RDHL |
|---|---|---|
| Price | $0.74 | $0.57 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 33.9M | 2.5M |
| Earning Date | 03-19-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $869,460.00 | N/A |
| Revenue This Year | $739.37 | $381.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.21 | $0.54 |
| 52 Week High | $2.75 | $2.79 |
| Indicator | NCPL | RDHL |
|---|---|---|
| Relative Strength Index (RSI) | 63.81 | 40.80 |
| Support Level | $0.37 | N/A |
| Resistance Level | $0.84 | $0.85 |
| Average True Range (ATR) | 0.16 | 0.11 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 52.34 | 2.77 |
Netcapital Inc is a financial technology company. The company facilitates the growth of private companies by providing fundraising services and other consulting services. The company's online private investment platform connects entrepreneurs and investors, enabling companies to raise capital digitally. The Company operates in a single operating segment, which is the provision of fintech services.
RedHill Biopharma Ltd is a specialty biopharmaceutical company mainly focused on the U.S. development and commercialization of drugs for GI diseases, infectious diseases, and oncology. The Company is mainly focused on the advancement of its development pipeline of clinical-stage therapeutic candidates and also commercializes its GI-related product, Talicia (omeprazole, amoxicillin, and rifabutin) in the U.S. Its therapeutic candidates include opaganib, RHB-204, RHB-104, RHB-102 (Bekinda), and RHB-107.